Pharmaceutical News

RSS

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

Researchers determine the neutralizing activity of four mAbs against ten strains of SARS-CoV-2.

9 Jan 2022

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

In a recently published article in the journal Nano-Micro Letters, scientists have provided an in-depth review on the application and benefits of nanotechnology in the development of coronavirus disease 2019 (COVID-19) vaccines.

7 Jan 2022

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

Researchers examine the efficacy of mRNA COVID-19 vaccination in NSCLC patients.

6 Jan 2022

How effective are COVID-19 vaccines against the Omicron and Delta variants?

Researchers study the effectiveness of COVID-19 vaccines against the SARS-CoV-2 Omicron and Delta variants.

6 Jan 2022

COVID-19 vaccines effective at varying intensities of SARS-CoV-2 exposure

Researchers investigate the effectiveness of COVID-19 vaccines in individuals at high risk due to their proximity with infected individuals.

6 Jan 2022

Study examines if antidepressants can benefit patients with osteoarthritis

A clinical trial published in Arthritis & Rheumatology recently examined whether duloxetine, a medication that is prescribed to treat depression and may also reduce chronic pain, can benefit patients with hip or knee osteoarthritis.

6 Jan 2022

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

Standard chemotherapies may efficiently kill cancer cells, but they also pose significant risks to healthy cells, resulting in secondary illness and a diminished quality of life for patients. To prevent the previously unavoidable damage, researchers, led by Penn State, have developed a new class of nanomaterials engineered to capture chemotherapy drugs before they interact with healthy tissue.

6 Jan 2022

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Researchers determine the cross-reactivity of the SARS-CoV-2 spike glycoprotein-induced antibodies before and after a third SARS-CoV-2 vaccine dose.

5 Jan 2022

Monoclonal antibody treatment of COVID-19 reduces viral shedding

Researchers aim to understand the potential benefits of mAbs in preventing and treating SARS-CoV-2 infection.

5 Jan 2022

FAU researchers urge to prescribe aspirin based on benefit-to-risk not age

Recent guidelines have restricted aspirin use in the primary prevention of cardiovascular disease to patients under 70, and more recent guidance to patients under 60. Yet, the risks of heart attacks and strokes increase markedly with age.

5 Jan 2022

Study leads to reduction in the number of medicines prescribed for older people

A study by researchers at RCSI University of Medicine and Health Sciences of GP-delivered medication for older people led to an overall reduction in the number of medicines prescribed.

5 Jan 2022

Study highlights opioid use disorder treatment access disparities based on Medicaid prevalence

Researchers report that in communities where Medicaid is a more common source of insurance, providers of buprenorphine, an effective treatment for opioid use disorder (OUD), are much less likely to discriminate between Medicaid and privately insured prospective patients, but patients with either type of coverage still face many barriers to obtaining an initial appointment for treatment.

5 Jan 2022

Medical marijuana users brace for shortages as Montana’s recreational market opens

More than a year after voters approved legalizing marijuana for recreational use in Montana, anyone older than 21 can now enter a dispensary and buy cannabis. That has medical marijuana user Joylynn Mane Wright worried.

5 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King's College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously.

4 Jan 2022

Pharmaceutical News

SARS‑CoV‑2 Omicron variant escapes monoclonal antibodies

From laboratory to clinic - Nanotechnology-enabled mRNA COVID-19 vaccines

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

How effective are COVID-19 vaccines against the Omicron and Delta variants?

COVID-19 vaccines effective at varying intensities of SARS-CoV-2 exposure

Study examines if antidepressants can benefit patients with osteoarthritis

New engineered nanomaterials help capture chemotherapy drugs to avoid tissue damage

Booster dose elicits cross-reactive humoral immunity against SARS-CoV-2 Delta and Omicron variants

Monoclonal antibody treatment of COVID-19 reduces viral shedding

FAU researchers urge to prescribe aspirin based on benefit-to-risk not age

Study leads to reduction in the number of medicines prescribed for older people

Study highlights opioid use disorder treatment access disparities based on Medicaid prevalence

Medical marijuana users brace for shortages as Montana’s recreational market opens

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Israeli study confirms drop in BNT162b2 efficacy after six months

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Minimal nAb titers against Omicron in the elderly after 3rd dose

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News